- Half-year results show revenue growth of 7% to € 5.2 million (H1 2022: € 4.9 million)
- Marinosolv: Business development activities for Tacrosolv and Budesolv in full force
- Carragelose: Successful market entry with nasal spray in Mexico, launch of new eye drop product and positive clinical data support extension into allergic indications
- Solv4U: First long-term partnership and patent efforts in China
- Outlook: Weaker H2 2023 expected but strong growth pipeline for 2024 and beyond
The full press release is available here: